GHENT, Belgium, 5 January 2016 – Ablynx [Euronext Brussels: ABLX; OTC: ABLYY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Abingworth Management Limited and Abingworth LLP.

Abingworth Management Limited notified Ablynx that they have dropped below the 3% threshold and now hold 1,594,401 Ablynx shares, which represent 2.91% of the current 54,812,374 outstanding Ablynx shares. Abingworth LLP holds 615,644 Ablynx shares, representing 1.12% of the current outstanding Ablynx shares. The combined holding of Abingworth Management Limited and Abingworth LLP is now 2,210,045 Ablynx shares, which represents 4.03% of the current 54,812,374 outstanding Ablynx shares.

Abingworth LLP (“ALLP”) acts as manager of Abingworth Bioventures (“ABV”) V LP and Abingworth Bioequities Master Fund Limited and exercises voting rights for shares held by those funds. Abingworth Management Limited (“AML”) acts as manager of ABV IV LP and ABV IV Executives LP and has engaged ALLP to assist it in the provision of fund management services for those funds. An investment Committee comprised of the same individuals at ALLP effectively exercises voting rights for funds managed by AML as well as funds managed by ALLP.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

@AblynxABLYX
Ablynx media relations:
Instinctif Partners
International/English language  Belgium/Dutch and French language
Sue Charles, Daniel Gooch  Jim Rusagara
London office  Brussels office
t: +44 (0)20 7866 7905  t: +32 (0)2 626 9500
e: ablynx@instinctif.com  e: ablynx@instinctif.com

Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.